Biolog-id Branches out to the United States with a New Operational Center in Atlanta
Biolog-id, a world leader in connected health solutions, today announced the establishment of its U.S. operational center in Atlanta. This new site will enable Biolog-id to continue the growth of its presence in North America and offer its business solutions in the biggest health market in the world.
Biolog-id LLC’s offices are located in Alpharetta, 15 minutes north of Atlanta, Georgia. Pierre Parent, President of Biolog-id, has named Amit Mayer as the General Manager of the subsidiary.
Amit Mayer is an experienced manager with a variety of experience in the health, innovation, marketing and education domains. As an entrepreneur, consultant, teacher and businessman, Amit has worked for high-profile businesses and organizations throughout the world and is particularly interested in the healthcare sector. He has been based in Atlanta for the last 5 years.
“Biolog-id has developed unique expertise in connected health solutions and has created a ground-breaking innovation which enables the reliable tracking of sensitive therapeutic products (red blood cell concentrates, platelets, plasma, and chemotherapy products), and ensures their safe administration to patients. By establishing a permanent presence in the US, Biolog-id aims to offer local clients quality support for its product offerings in America. This operational center will manage sales, sales support, operations and R&D. “Biolog-id is poised to establish itself in the US market and we are convinced Amit is the right person to make this a success”, says Pierre Parent.
“Biolog-id’s solutions are based on the Internet of Things (IoT), which improves the quality and safety of medical procedures and patient care by ensuring that the right product is administered to the right patient, and allowing healthcare professionals to devote more time to patient”, adds Amit Mayer. “They can be entirely integrated into existing work processes and provide significant financial savings by reducing product loss and optimizing the supply chain (reducing stock, remote management with no manual handling, etc.). In addition, Biolog-id’s solutions also help improve working conditions for healthcare professionals by relieving them of time-consuming administrative and logistical tasks. This transatlantic site is testament to our aim to make use of all our synergies to provide the North-American market with a one-of-a-kind service offering. By forming a team that is focused on adapting solutions to the specific features of blood transfusion centers, hospital blood banks and pharmacies responsible for injectable products, Biolog-id aims to provide ad hoc solutions with significant added value, enabling our rapid growth in North America.”
Biolog-id was founded in 2005 based on a pioneering concept: using RFID technology to identify, track and manage sensitive health products (red blood cells, plasma, platelets, chemotherapy products). This ground-breaking innovation enabled the development of a totally unique product: the “Biolog solution” and its intellectual property rights, currently amounting to 100 or so international patents.
The company’s corporate office is located in Paris and its manufacturing and product and customer support facility is situated in Bernay in the Normandie region of France. It currently employs approximately 80 people and is continuing its recruitment plan both in France and abroad. www.biolog-id.fr
Amit Mayer, +1 404 953 3169
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Piraeus Bank Presents the Principles for Responsible Banking with the Governor of the Bank of Greece16.1.2019 18:21 | Pressemelding
The Principles for Responsible Banking were presented today for the first time in Greece at an event organized by Piraeus Bank with Mr. Yannis Stournaras, the Governor of the Bank of Greece, as the keynote speaker. The event was organised as part of Piraeus Bank’s commitment to the United Nations Environment Programme Finance Initiative (UNEP FI). Piraeus is the only Greek bank to be a member of the global initiative, which includes twenty-eight banks from around the world, representing over USD 17 trillion in combined assets. Mr. Yannis Stournaras, the Governor of Bank of Greece, highlighted in his speech that the Bank of Greece fully supports the Principles for Responsible Banking and urges all of the banks to endorse the Principles and set ambitious targets. The Bank of Greece was one of the first central banks to become involved with the climate change issue, establishing the Climate Change Impacts Study Committee in 2009 and investing in one of the most significant Sustainable Dev
Arrowgrass Has Agreed to an Extension of Its Irrevocable Undertaking Regarding Its Holdings in Basware Corporation16.1.2019 17:30 | Pressemelding
The investment funds of Arrowgrass Capital Partners LLP (“Arrowgrass”) hold, directly and indirectly, over 24 per cent of all shares and votes in Basware Corporation (“Basware”), a Finnish listed company providing networked source-to-pay solutions and e-invoicing services. Arrowgrass refers to the announcements made by Basware on 16 November 2018, 20 November 2018 and 7 December 2018 with regard to a possible tender offer by Tradeshift Holdings Inc. (“Tradeshift”) for Basware. Arrowgrass announces that it has agreed, under certain conditions, to extend an irrevocable undertaking with Tradeshift to accept a tender offer by Tradeshift for Basware, should Tradeshift publicly announce its tender offer in accordance with applicable laws and regulations no later than 28 February, 2019. Arrowgrass recognizes that Basware has emphasized in its announcements that the launch of the tender offer remains uncertain. About Arrowgrass Arrowgrass Capital Partners LLP is a London headquartered alternat
PCI Security Standards Council Publishes New Software Security Standards16.1.2019 15:25 | Pressemelding
Today, the PCI Security Standards Council (PCI SSC) published new requirements for the secure design and development of modern payment software. The PCI Secure Software Standard and the PCI Secure Lifecycle (Secure SLC) Standard are part of a new PCI Software Security Framework, which includes a validation program for software vendors and their software products and a qualification program for assessors. The programs will be launched later in 2019. “Innovation in payments is moving at an incredible pace. Each advancement provides the industry the opportunity to develop applications more quickly and efficiently than before and to design software for new platforms for payment acceptance,” said PCI SSC Chief Technology Officer Troy Leach. “The new PCI Secure Software Standard and PCI Secure SLC Standard support this evolution in payment software practices by providing a dynamic way for developers to demonstrate their software protects payment data for the next generation of applications.”
Keio Plaza Hotel Hosts “Hina-matsuri (Girls’ Doll Festival)” Event – 6,800 Magnificent Hanging Art Ornaments and Tea Ceremony Culture16.1.2019 14:05 | Pressemelding
Keio Plaza Hotel Tokyo (KPH), one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, will host an event entitled “Hina-matsuri through Tea Ceremony Culture and Hanging Art” to help guests celebrate Japan’s cultural event known as Girls’ Doll Festival or “Hina-matsuri” from February 1 (Friday) to March 28 (Thursday), 2019 with magnificent hanging art ornaments displayed in our lobby and special menu items served in our restaurants. In addition to the display of some 6,800 magnificent and ornate handmade dolls and other traditional decorations in this coming event, our Hotel will also display various traditional and historical art items used in traditional Japanese tea ceremony, which has long been a part of the cultural upbringing of Japanese women from the Meiji Period (1868 to 1912). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190116005191/en/ About 6,800 hanging decorative art ornaments meticul
Virgin Voyages Calling All RockStars to Sea16.1.2019 14:00 | Pressemelding
Virgin Voyages, the new lifestyle brand set to disrupt the travel industry, today released several designs and images of their RockStar Suites. The new company is throwing out traditional clichés on luxury and formalities, and instead bringing Rebellious Luxe to life at sea with their RockStar Suites designed by Tom Dixon’s Design Research Studio as the pinnacle of that experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190116005444/en/ Massive Suite Living Room. (Photo: Business Wire) Highlights of the Massive Suite, the top suite aboard the Scarlet Lady, include its very own guitar-clad music room, views of the ocean from every corner of the suite, and a massive terrace complete with its own Peek-a-View outdoor shower, hot tub, hammocks and a runway outdoor dining table, where a staircase will help Sailors make their way on top of the table for dancing. “Virgin has always avoided stuffy formalities and brought a lo
Janssen announces European Commission approval of ERLEADA® (apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease16.1.2019 13:24 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has granted marketing authorisation for ERLEADA® (apalutamide), a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. The EC approval is based on data from the pivotal Phase 3 SPARTAN study, which was published in The New England Journal of Medicine. The study assessed the efficacy and safety of apalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in patients with nmCRPC who had a rapidly rising prostate specific antigen (PSA) level despite receiving continuous ADT. Findings from the study showed that apalutamide plus ADT, significantly reduced the risk of developing distant metastasis or death (metastasis free survival [MFS]) by 72 percent, compared to placebo in combination with ADT (HR = 0.28; 95% CI, 0